COVID-19 pandemic
Swissmedic approves the extension of booster doses of the Pfizer–BioNTech COVID-19 vaccine to people over the age of 16 years as well as high-risk people over the age of 12 years.
Sources: The Times of India
Changes
- Swissmedic approves the extension of booster dose of the Pfizer-BioNTech COVID-19 vaccine to people aged above 16 years as well as high-risk people aged above 12.
- Swissmedic approves the extension of booster doses of the Pfizer–BioNTech COVID-19 vaccine to people over the age of 16 years as well as high-risk people over the age of 12 years.